ReviewReviews in cardiovascular medicine2025
Cardiac Involvement in Systemic Lupus Erythematosus.
Review in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Severe Mitral Regurgitation and Constrictive Pericarditis in a Patient with Systemic Lupus Erythematosus.CASE (Philadelphia, Pa.) · 2026Article
- Serum vs. tissue cytokine dysregulation in SLE-associated myocarditis: a hypothesis from an African cohort perspective.Molecular medicine (Cambridge, Mass.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease caused by the production of autoantibodies, which form pathogenic immune complexes that deposit in multiple organs, leading to the multisystem involvement characteristic of SLE. Cardiovascular complications contribute substantially to the morbidity and mortality associated with SLE. Thus, this review discusses the cardiac manifestations of SLE, including the epidemiology, risk factors, pathogenesis, clinical features, diagnosis, and treatment options. Furthermore, we discuss the role of autoantibodies, endothelial dysfunction, and immune complex-mediated injury in the pathogenesis of SLE. Finally, we discuss emerging therapies and future research directions aimed at mitigating cardiac complications in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.